

2022

Catalog

promise
ADVANCED PROTEOMICS

SIL-PROTEINS

FOR TARGETED LC-MS QUANTIFICATION



The gold standard for robust and reliable quantitative LC-MS workflow

www.promise-proteomics.com | contact@promise-proteomics.com

SIL-PROTEINS

Promise Proteomics is a pioneer and expert in mass spectrometry-based quantification methods development and in bioproduction of Stable Isotope Labelled (SIL) proteins

Why using our SIL-Protein ?

Our SIL-proteins are the gold standard for quantitative LC-MS.

SIL-Proteins correct bias occurring during the preparation and analytical workflow and due to losses, incomplete digestion, adsorption, proteolysis... With SIL-Proteins, the accuracy and reproducibility of your quantification data is improved.


This product is useful for :

- Bioanalysis pharmacokinetics studies (clinical & nonclinical),
- Research and Discovery/pre-clinical/clinical drug development
- Biomarker's quantification

Characteristics

- Full length recombinant proteins
- Identical to the protein of interest, same sequence as native protein
- High isotopic incorporation, stability and purity
- Uniform or specific labelling, ^{13}C , ^{15}N isotope
- Unlabelled option

How to use it ?



Unlike the use of SIL-peptides, Promise's SIL-proteins are processed along with the target analytes throughout the pre-analytical and LC-MS workflow.

OFF-THE-SHELF PRODUCTS

SIL-Proteins* are available to support your innovative and ambitious studies



28
proteins

Human Proteins	Unlabelled	Labelled
Neuroscience/Psychiatric diseases biomarkers		
Apolipoprotein E3	❖	U15N ❖
Neurofilament	❖	(Arg,Lys) 13C15N ❖
Synuclein alpha	❖	(Arg,Lys) 13C15N ❖
Synuclein beta		U15N ❖
Synuclein gamma		U15N ❖
Tau 441	❖	(Arg,Lys) 13C15N ❖
Tau 352		U15N ❖
Cardiovascular disease biomarkers		
Apolipoprotein A1	❖	U15N ❖
Carboxypeptidase B2		(Arg,Lys) 13C15N ❖
Clusterin protein		(Arg,Lys) 13C15N ❖
NT-proBNP	❖	U15N ❖
Troponin I		U15N ❖
Metabolic biomarkers		
Albumin		U15N ❖
Cystatin C	❖	U15N ❖
Erythropoietin		(Arg,Lys) 13C15N ❖
Growth hormone 22	❖	U15N ❖
Vitamin D binding Protein		(Arg,Lys) 13C15N ❖
Cancer biomarkers		
Alpha Feto Protein		(Arg,Lys) 13C15N ❖
Choriogonadotropin		(Arg,Lys) 13C15N ❖
KRAS 2A	❖	U15N ❖
KRAS 2B G12C mutant	❖	(Arg,Lys) 13C15N ❖
KRAS 2B G12C/C118A mutant	❖	
KRAS 2B 12C/C51S/C80L/C118S	❖	
KRAS 2B G12D mutant		(Arg,Lys) 13C15N ❖
KRAS 2B G13C mutant		(Arg,Lys) 13C15N ❖
KRAS 2B G13D mutant		(Arg,Lys) 13C15N ❖
NRAS	❖	U15N ❖
Sepsis biomarker		
Procalcitonin	❖	U15N ❖

*for Research Use Only

Your protein of interest is not listed ?

For 10 years with more than 150 proteins produced, Promise Proteomics offers custom bioproduction options. Contact us for further information.



For any further information or to request a quote :
✉ orders@promise-proteomics.com

REFERENCES

Publications citing our Stable Isotope Labelled Proteins and endorsing their quality and suitability for quantitative LC-MS work

References using our proteins

- **Clinical Cancer Research**

Wheeler, J. and al. (2022). Quantitation of thrombin-activatable fibrinolysis inhibitor in human plasma by isotope dilution mass spectrometry. *Analytical Biochemistry*. <https://doi.org/10.1016/j.ab.2021.114413>

- **National Institute for Biological Standards and Control**

Liyasova, M. and al. (2021). A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM). <https://doi.org/10.1158/1078-0432.ccr-21-0649>

- **Janssen Pharmaceutica**

Bijttebier, S. and al. (2021). Development of immunoprecipitation – two-dimensional liquid chromatography – mass spectrometry methodology as biomarker read-out to quantify phosphorylated tau in cerebrospinal fluid from Alzheimer disease patients. <https://doi.org/10.1016/j.chroma.2021.462299>

- **Rapid Novor**

McDonald, Z. and al. (2021). Mass Spectrometry Provides a Highly Sensitive Noninvasive Means of Sequencing and Tracking M-Protein in the Blood of Multiple Myeloma Patients. <https://doi.org/10.1021/acs.jproteome.0c01022>

- **Merck**

Lassman, M. E. and al. (2021). Experimental Medicine Study to Measure Immune Checkpoint Receptors PD-1 and GITR Turnover Rates In Vivo in Humans. <https://doi.org/10.1002/cpt.2129>

- **Merck**

Vasicek, L. A. and al. (2019). Direct quantitation of therapeutic antibodies for pharmacokinetic studies using immuno-purification and intact mass analysis. *Bioanalysis*, 11(3), 203-213. <https://doi.org/10.4155/bio-2018-0240>

- **University Medical Center Utrecht**

el Amrani, M. and al (2019). Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry : Infliximab as proof of principle. *Journal of Translational Autoimmunity*, 1, 100004. <https://doi.org/10.1016/j.jtauto.2019.100004>

- **National Institute of Standards and Technology**

Schneck, N. A., and al. (2018). Quantification of cardiac troponin I in human plasma by immunoaffinity enrichment and targeted mass spectrometry. *Analytical and Bioanalytical Chemistry*, 410(11), 2805-2813. <https://doi.org/10.1007/s00216-018-0960-7>

- **Hospices Civils de Lyon**

Millet, A. and al. (2019). Determination of Cetuximab in Plasma by Liquid Chromatography-High-Resolution Mass Spectrometry Orbitrap With a Stable Labeled ¹³C,¹⁵N-Cetuximab Internal Standard. *Therapeutic Drug Monitoring*, 41(4), 467-475. <https://doi.org/10.1097/ftd.0000000000000613>

- **University Hospital Grenoble-Alpes**

Jourdil, J. F. and al. (2018). Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry. *Therapeutic Drug Monitoring*, 40(4), 417-424. <https://doi.org/10.1097/ftd.0000000000000514>

- **Wellspring Biosciences**

Hansen, R. and al. (2018). An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors. *Scientific Reports*, 8(1). <https://doi.org/10.1038/s41598-018-32683-w>

- **Wellspring Biosciences**

Janes, M. R. and al. (2018). Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. *Cell*, 172(3), 578–589.e17. <https://doi.org/10.1016/j.cell.2018.01.006>

- **Merck**

Vasicek, L. A. and al. (2017). Quantitation of a Therapeutic Antibody in Serum Using Intact Sequential Affinity Capture, Trypsin Digestion, and LC-MS/MS. *Analytical Chemistry*, 90(1), 866-871. <https://doi.org/10.1021/acs.analchem.7b03716>

- **University Hospital Grenoble-Alpes**

Maes, P. and al. (2017). Introducing plasma/serum glycodepletion for the targeted proteomics analysis of cytolysis biomarkers. *Talanta*, 170, 473-480. <https://doi.org/10.1016/j.talanta.2017.04.042>

- **University Hospital Grenoble-Alpes**

Gilquin, B. and al. (2017). Multiplex and accurate quantification of acute kidney injury biomarker candidates in urine using Protein Standard Absolute Quantification (PSAQ) and targeted proteomics. *Talanta*, 164, 77-84. <https://doi.org/10.1016/j.talanta.2016.11.023>

- **University Hospital Grenoble-Alpes**

Jourdil, J. F. and al. (2016). Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry : towards a standardization of the methods ? *Analytical and Bioanalytical Chemistry*, 409(5), 1195-1205. <https://doi.org/10.1007/s00216-016-0045-4>

- **University Medical Center Utrecht**

el Amrani, M. and al. (2016). Quantification of active infliximab in human serum with liquid chromatography-tandem mass spectrometry using a tumor necrosis factor alpha -based pre-analytical sample purification and a stable isotopic labeled infliximab bio-similar as internal standard : A target-based, sensitive and cost-effective method. *Journal of Chromatography A*, 1454, 42-48. <https://doi.org/10.1016/j.chroma.2016.05.070>

- **Centre d'Immunologie Pierre Fabre (CIPF)**

Lebert, D. and al. (2015). Absolute and multiplex quantification of antibodies in serum using PSAQTM standards and LC-MS/MS. *Bioanalysis*, 7(10), 1237-1251. <https://doi.org/10.4155/bio.15.56>

- **University Hospital Grenoble-Alpes**

Lebert, D. and al. (2014). DIGESTIF : A Universal Quality Standard for the Control of Bottom-Up Proteomics Experiments. *Journal of Proteome Research*, 14(2), 787-803. <https://doi.org/10.1021/pr500834z>

- **Merck**

McAvoy, T. and al. (2014). Quantification of Tau in Cerebrospinal Fluid by Immunoaffinity Enrichment and Tandem Mass Spectrometry. *Clinical Chemistry*, 60(4), 683-689. <https://doi.org/10.1373/clinchem.2013.216515>

- **LGC Group**

Pritchard, C. and al. (2014). Quantification of Human Growth Hormone in Serum with a Labeled Protein as an Internal Standard : Essential Considerations. *Analytical Chemistry*, 86(13), 6525-6532. <https://doi.org/10.1021/ac501032q>

- **LGC Group**

Pritchard, C. and al. (2013). The Role of Ion Mobility Spectrometry-Mass Spectrometry in the Analysis of Protein Reference Standards. *Analytical Chemistry*, 85(15), 7205-7212. <https://doi.org/10.1021/ac400927s>

- **INSERM**

Picard, G. and al. (2012). PSAQTM standards for accurate MS-based quantification of proteins : from the concept to biomedical applications. *Journal of Mass Spectrometry*, 47(10), 1353-1363. <https://doi.org/10.1002/jms.3106>

- **INSERM**

Adrait, A. and al. (2012). Development of a Protein Standard Absolute Quantification (PSAQTM) assay for the quantification of Staphylococcus aureus enterotoxin A in serum. *Journal of Proteomics*, 75(10), 3041-3049. <https://doi.org/10.1016/j.jprot.2011.11.031>

- **INSERM**

Huillet, C. and al. (2012). Accurate Quantification of Cardiovascular Biomarkers in Serum Using Protein Standard Absolute Quantification (PSAQTM) and Selected Reaction Monitoring. *Molecular & Cellular Proteomics*, 11(2), M111.008235. <https://doi.org/10.1074/mcp.m111.008235>

- **INSERM**

Lebert, D., Dupuis, A., Garin, J., Bruley, C., & Brun, V. (2011). Production and Use of Stable Isotope-Labeled Proteins for Absolute Quantitative Proteomics. *Methods in Molecular Biology*, 93-115. https://doi.org/10.1007/978-1-61779-148-2_7